Stay updated on Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial page.

Latest updates to the Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial page
- Check2 days agoChange DetectedThe location label for site 704 was updated from 'Tainan City, Taiwan, 704' to 'Tainan, Taiwan, 704'. A government funding-status notice text was removed from the page.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedEnrollment is updated to 959 participants and the study's last update is posted on 2025-08-11. Primary completion is 2025-03-20 and estimated study completion is 2025-09-30.SummaryDifference0.1%

- Check45 days agoChange DetectedDifference1%

- Check52 days agoChange DetectedPage content is updated to revision v3.1.0 and several MedlinePlus topics are removed; overall, no substantial new information is added and core content remains unchanged.SummaryDifference0.2%

- Check67 days agoChange DetectedMinor update: version bumped from v3.0.1 to v3.0.2 and the Back to Top element was removed; core content remains unchanged.SummaryDifference0.1%

- Check74 days agoChange DetectedThe location name has been updated from 'Tuen Mun, Hong Kong' to 'Tuenmen, Hong Kong', and the version number has changed from v3.0.0 to v3.0.1.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial page.